Related Experiment Video
Updated: Aug 21, 2026

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency
Ari Bitnun1, Etienne Sochett, Paul T Dick
1Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. ari.bitnun@sickkids.ca
Insights
Protease inhibitor (PI) therapy in HIV-infected children reduces insulin sensitivity and beta-cell function, potentially leading to impaired glucose tolerance. This suggests early metabolic syndrome features in children on PI-containing antiretroviral therapy.
Area of Science:
- Pediatric Endocrinology
- Infectious Diseases
- Metabolic Syndrome
Background:
- Previous studies have not clearly linked protease inhibitor (PI) therapy to glucose metabolism issues in HIV-infected children.
- Understanding the impact of PI therapy on glucose homeostasis is crucial for managing pediatric HIV.
Purpose of the Study:
- To precisely define the effect of PI therapy on glucose homeostasis in HIV-infected children.
- To investigate the relationship between PI therapy, insulin sensitivity, and body composition.
Main Methods:
- Insulin-modified frequent-sampling intravenous glucose tolerance test (FSIGT) in 33 PI-treated and 15 PI-naive HIV-infected children.
- Assessment of fasting lipids, glucose, insulin, C-peptide, and abdominal CT scans for visceral adipose tissue.
- Oral glucose tolerance test (OGTT) in a subset of PI-treated children.
Main Results:
- PI-treated children showed significantly lower insulin sensitivity index and disposition index compared to PI-naive children after adjusting for confounders.
- Insulin sensitivity in PI-treated children inversely correlated with visceral adipose tissue area and visceral to subcutaneous adipose tissue ratio.
- Four out of 21 PI-treated subjects exhibited impaired glucose tolerance.
Conclusions:
- PI therapy in HIV-infected children impairs insulin sensitivity and beta-cell response, potentially causing impaired glucose tolerance.
- PI-containing highly active antiretroviral therapy is associated with early metabolic syndrome-like features, including insulin resistance and dyslipidemia.
Abstract:
Previous pediatric studies have failed to demonstrate a clear association between protease inhibitor (PI) therapy and abnormal glucose homeostasis in HIV-infected children. To define more precisely the impact of PI therapy on glucose homeostasis in this population, we performed the insulin-modified frequent-sampling iv glucose tolerance test on 33 PI-treated and 15 PI-naive HIV-infected children. Other investigations included fasting serum lipids; glucose, insulin, and C-peptide; single-slice abdominal computed tomography; and, in a subset of PI-treated children, an oral glucose tolerance test. There were no differences between the two groups with respect to fasting serum insulin or C-peptide, homeostatic model assessment insulin resistance, or quantitative insulin sensitivity check index. The mean insulin sensitivity index of PI-treated and PI-naive children was 6.93 +/- 6.37 and 10.58 +/- 12.93 x 10(-4)min(-1) [microU/ml](-1), respectively (P = 0.17). The mean disposition index for the two groups was 1840 +/- 1575 and 3708 +/- 3005 x 10(-4)min(-1) (P = 0.013), respectively. After adjusting for potential confounding variables using multiple regression analysis, the insulin sensitivity index and disposition index of PI-treated children were significantly lower than that of PI-naive children (P = 0.01 for both). In PI-treated but not PI-naive children, insulin sensitivity correlated inversely with visceral adipose tissue area (r = -0.43, P = 0.01) and visceral to sc adipose tissue ratio (r = -0.49, P = 0.004). Mildly impaired glucose tolerance was noted in four of 21 PI-treated subjects tested. Our results demonstrate not only that PI therapy reduces insulin sensitivity in HIV-infected children but also that it impairs the beta-cell response to this reduction in insulin sensitivity and, in a subset of children, leads to the development of impaired glucose tolerance. The presence of insulin resistance, dyslipidemia, and the significant correlation of reduced insulin sensitivity with increased visceral adipose tissue content suggest that PI-containing highly active antiretroviral therapy is associated with the emergence of early features of a metabolic syndrome-like phenotype.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Inhibitors of Virion Maturation and Assembly
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Insulin Secretory Vesicles

